Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Study Of The Effect Of CP-751,871 In Combination With Gemcitabine And Cisplatin In Patients With Advanced Non-Small Cell Lung Cancer (ADVIGO1017)

This study has been withdrawn prior to enrollment.
Sponsor:
Information provided by:
Pfizer
ClinicalTrials.gov Identifier:
NCT00907504
First received: May 20, 2009
Last updated: June 16, 2014
Last verified: June 2014
  Purpose

Gemcitabine and cisplatin given together is a standard treatment option for advanced lung cancer patients. The purpose of this study is to assess if the life span is longer in patients taking the investigational drug CP-751,871 in combination with gemcitabine and cisplatin compared to gemcitabine and cisplatin alone. Considering a 10% rate of drop-outs, 1,210 participants will be required in order to have an adequate sample size (1,100 evaluable patients) and power to detect a 30% prolongation of survival on the experimental arm.


Condition Intervention Phase
Carcinoma, Non-Small-Cell Lung
Drug: CP-751,871
Drug: Cisplatin
Drug: Gemcitabine
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Randomized, Open Label, Phase 3 Clinical Study To Evaluate The Effect Of The Addition Of CP-751,871 To Gemcitabine And Cisplatin In Patients With Advanced Non-Small Cell Lung Cancer

Resource links provided by NLM:


Further study details as provided by Pfizer:

Primary Outcome Measures:
  • Overall Survival [ Time Frame: Dec 2012 ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Progression Free survival [ Time Frame: Dec 2011 ] [ Designated as safety issue: No ]
  • Objective Response [ Time Frame: Dec 2011 ] [ Designated as safety issue: No ]
  • Overall Safety Profile [ Time Frame: Dec 2012 ] [ Designated as safety issue: No ]
  • Patient Reported Outcome [ Time Frame: Dec 2012 ] [ Designated as safety issue: No ]
  • Pharmacokinetics [ Time Frame: Dec 2012 ] [ Designated as safety issue: No ]
  • Anti-drug Antibody [ Time Frame: Dec 2012 ] [ Designated as safety issue: No ]
  • Biomarker Analysis [ Time Frame: Dec 2012 ] [ Designated as safety issue: No ]

Enrollment: 0
Study Start Date: July 2010
Estimated Study Completion Date: May 2014
Estimated Primary Completion Date: May 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: CP-751,871 + Gemcitabine + Cisplatin
investigational arm
Drug: CP-751,871
CP-751,871 20mg/kg every 3 weeks
Drug: Cisplatin
Cisplatin 80 mg/m2 every 3 weeks
Drug: Gemcitabine
Gemcitabine 1,250 mg/m2 Day1+8 of evey 3 week-cycle
Active Comparator: Gemcitabine + Cisplatin
standard of care
Drug: Cisplatin
Cisplatin 80 mg/m2 every 3 weeks
Drug: Gemcitabine
Gemcitabine 1,250 mg/m2 Day1+8 of evey 3 week-cycle

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Non-Small Cell Lung Cancer (NSCLC), advanced, chemotherapy-naive
  • Male or female > 18 years
  • Eastern Oncology Cooperative Group (ECOG) Performance Status (PS) 0 or 1
  • Adequate organ function

Exclusion Criteria:

  • Uncontrolled hypertension or diabetes;
  • Pregnant female;
  • Symptomatic Central Nervous System (CNS) metastasis, requirement for chronic corticosteroids.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00907504

Sponsors and Collaborators
Pfizer
Investigators
Study Director: Pfizer CT.gov Call Center Pfizer
  More Information

Additional Information:
No publications provided

Responsible Party: Director, Clinical Trial Disclosure Group, Pfizer, Inc.
ClinicalTrials.gov Identifier: NCT00907504     History of Changes
Other Study ID Numbers: A4021017
Study First Received: May 20, 2009
Last Updated: June 16, 2014
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Carcinoma, Non-Small-Cell Lung
Bronchial Neoplasms
Carcinoma, Bronchogenic
Lung Diseases
Lung Neoplasms
Neoplasms
Neoplasms by Site
Respiratory Tract Diseases
Respiratory Tract Neoplasms
Thoracic Neoplasms
Cisplatin
Gemcitabine
Anti-Infective Agents
Antimetabolites
Antimetabolites, Antineoplastic
Antineoplastic Agents
Antiviral Agents
Enzyme Inhibitors
Immunologic Factors
Immunosuppressive Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Radiation-Sensitizing Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on November 20, 2014